ROIV

Bullish

Should Roivant’s One‑Off Driven Profitability Shift Require Action From Roivant Sciences (ROIV) Investors?

Roivant Sciences (ROIV) recently reported a swing to profitability in Q4 2026, driven by one-off items, despite a full-year sales decline. This unexpe...

Simply Wall Street 1 week ago 0

Bullish

Baron Fund Puts Spotlight On Roivant’s Brepocitinib And Valuation Gap

The Baron Health Care Fund has recently highlighted Roivant Sciences (NasdaqGS:ROIV) due to positive Phase 2 results for brepocitinib in cutaneous sar...

Simply Wall Street 3 weeks ago 0